Companies

Request More Information

Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Experts Commenting on This Company

 

Visit Company Website

View Company News


Omeros Corp.

TICKER: OMER:NASDAQ

Omeros Corp. is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Lead drug product Omidria (OMS302) for lens replacement surgery is under review for marketing approval by both FDA and the European Medicines Agency, with U.S. commercial launch planned for H2/14. Omeros' five other clinical programs are focused on schizophrenia; Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros' proprietary G protein-coupled receptor (GPCR) platform is making available many new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.


The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

Jason Kolbert, Maxim Group (3/11/14) "Omeros Corp. announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. . .the data suggests that OMS721 significantly inhibited complement deposition in the model using serum samples from aHUS patients obtained during the acute phase of disease. . .the potential of the Omeros MASP-2 antibody is significant, in our opinion. MASP-2 is the only protein unique to, and required for, the function of the lectin complement pathway."

The Life Sciences Report Interview with George Zavoico (3/6/14) "Omeros [has] a number of features that I find interesting. First is the near-term approval of a niche product called Omidria, [an] irrigant for use in intraocular lens replacement surgery to reduce inflammation and postoperative pain. . . we think this is a low-cost, high margin and volume product that could generate about $100M in sales in 2016. . .possibly enough to bring Omeros to profitability that same year. . .

The new drug application for Omidria was filed back in the summer, and after that a marketing authorization application was filed with the European Medicines Agency. . .we expect a decision after the standard 10-month review—probably midyear or early Q3/14 for the FDA—with launch sometime before the end of 2014.

Behind Omidria, there's a robust pipeline that the company has advanced into a number of phase 1 and phase 2 trials. These are unique products that could be first-in-class for a number of interesting indications, including some central nervous system and inflammatory indications." More >

The Life Sciences Report Interview with Steve Brozak (2/6/14) "Omeros Corp. has a therapy platform that targets inflammation, whether it be ophthalmic or in joints, specifically in arthroscopic surgery. The idea is to reduce inflammation, thereby reducing postoperative pain and providing for much better outcomes. . .I think it would be easy for Omeros to single-handedly take the market." More >

Jason Kolbert, Maxim Group (2/5/14) "Omeros Corp.'s pipeline progress looks good: The company announced that the FDA granted fast-track designation to OMS824, the company's phosphodiesterase 10 inhibitor, for the treatment of cognitive impairment in patients with Huntington's disease. . .Omeros has conducted successful clinical trials assessing the safety, tolerability, pharmacokinetics and target engagement of a wide range of doses of OMS824 in its phase 1 program. Positive data from the company's OMS824 phase 2a schizophrenia trial were recently announced, and Omeros expects to begin enrolling patients this quarter in its phase 2 trial evaluating OMS824 for Huntington's disease."

Due to permission requirements, not all quotes are shown.

Omeros Corp. Content



Back to Top

Would you like additional information on Biotechnology/Pharmaceuticals companies?
YES
disable